LongOGNJun 2026
Organon & Co.
Sun Pharmaceuticals agreed to acquire Organon for $14.00 per share in cash. The deal remained subject to shareholder and antitrust approvals at the time of the commentary…
Gabelli Enterprise Mergers & Acquisitions Fund
Event-driven strategy focused on merger and acquisition situations and related corporate catalysts.$61M AUM2 published ideas
Gabelli Enterprise Mergers & Acquisitions Fund invests around announced and potential corporate transactions. The strategy seeks returns from deal spreads and other event-driven situations while managing transaction-specific risk.
Ideas from Gabelli Enterprise Mergers & Acquisitions Fund
LongCPRXJun 2026
Catalyst Pharmaceuticals Inc.
Angelini Pharma agreed to acquire Catalyst for $31.50 per share in cash. U.S. antitrust approval had been received and shareholders approved the transaction after quarter-end…
Letters covered
- Gabelli Funds Shareholder Commentary - Open-End FundsJune 30, 2026
Source PDFs are not republished here; only extracted ideas and quotes.